Congress Materials

Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
I am a U.S. Patient / CaregiverNo, go back to the patient portal
SelectI am a U.S. Patient / CaregiverNo, go back to the patient portal
Non-US residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Tamiya M, Goto Y, Kenmotsu H, Kurata T, Murakami S, Yanagitani N, Taniguchi H, Kuyama S, Shimizu J, Yokoyama T, Shimada N, Maeda T, Tamiya A, Uchiyama A, Imaizumi K, Takahama T, Nishio M, Hayashi H, Shiraiwa N, Okura M, Kikkawa H, Thomaidou D, Kato T August 7, 2022 WCLC 2022 Lung Cancer

A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan

View Presentation
Poster
Ng R, Zuraik C,  On PV,  Khoudigian S,  Sharma A,  Peloquin F,  Aita FF, Rupp M August 7, 2022 WCLC 2022 Lung Cancer

Lorlatinib for ALK+ NSCLC Patients Pretreated with Second-Generation ALK Inhibitors: Canadian Real-World Experience

View Presentation
Poster
Li J, Pu X, Zhang B, Zhang J, Mok TS, Nakagawa K, Rosell R, Cheng Y, Zhou X, Miglorino MR, Niho S, Lee KH, Corral J, Pluzanski A, Linke R, Pan F, Tang Y, Tan W, Wu L August 7, 2022 WCLC 2022 Lung Cancer

Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study

View Presentation